Pulmagen Therapeutics Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 11

Employees

  • Latest Deal Type
  • M&A

Pulmagen Therapeutics General Information

Description

Developer of a a novel inhaled therapy designed to treat chronic respiratory diseases. The company develops oral and inhaled medicines for chronic lung disease such as COPD, asthma and cystic fibrosis delivering both symptomatic relief and a disease modifying effect.

Contact Information

Website
www.pulmagen.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • The Coach House, Grenville Court
  • Britwell Road, Burnham
  • Slough SL1 8DF
  • England, United Kingdom
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Skyepharma
Vertical(s)
Life Sciences
Corporate Office
  • The Coach House, Grenville Court
  • Britwell Road, Burnham
  • Slough SL1 8DF
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pulmagen Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 14-Aug-2014 Completed Clinical Trials - Phase 2
1. Early Stage VC 01-Feb-2010 Completed Startup
To view Pulmagen Therapeutics’s complete valuation and funding history, request access »

Pulmagen Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a a novel inhaled therapy designed to treat chronic respiratory diseases. The company develops oral and inh
Biotechnology
Slough, United Kingdom
11 As of 2016

Burlington, MA
 

Essex, CT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pulmagen Therapeutics Competitors (30)

One of Pulmagen Therapeutics’s 30 competitors is Minerva Neurosciences, a Formerly VC-backed company based in Burlington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Minerva Neurosciences Formerly VC-backed Burlington, MA
Thetis Pharmaceuticals Venture Capital-Backed Essex, CT
Lung Therapeutics Formerly VC-backed Austin, TX
Moerae Matrix Formerly VC-backed Morristown, NJ
Verona Pharma Private Debt Financed London, United Kingdom
You’re viewing 5 of 30 competitors. Get the full list »

Pulmagen Therapeutics Patents

  • 192

    Total Documents Applications and Grants

  • Total Patents Families

  • 76

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

Pulmagen Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20140018345-A1 Inhibition of enzymes Active 12-Jul-2012
US-9199984-B2 Inhibition of enzymes Inactive 12-Jul-2012
GB-201210968-D0 Compounds Inactive 21-Jun-2012
JP-2011195593-A Quinuclidine derivative as muscarinic m3 receptor antagonist Pending 30-Jun-2011
GB-201109915-D0 Compounds Inactive 14-Jun-2011
To view Pulmagen Therapeutics’s complete patent history, request access »

Pulmagen Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pulmagen Therapeutics Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amundi Private Equity Funds PE/Buyout Minority
Forbion Venture Capital Minority
MVM Partners Growth/Expansion Minority
Molten Ventures Venture Capital Minority
TTP Venture Managers Corporate Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

Pulmagen Therapeutics FAQs

  • When was Pulmagen Therapeutics founded?

    Pulmagen Therapeutics was founded in 2010.

  • Where is Pulmagen Therapeutics headquartered?

    Pulmagen Therapeutics is headquartered in Slough, United Kingdom.

  • What is the size of Pulmagen Therapeutics?

    Pulmagen Therapeutics has 11 total employees.

  • What industry is Pulmagen Therapeutics in?

    Pulmagen Therapeutics’s primary industry is Biotechnology.

  • Is Pulmagen Therapeutics a private or public company?

    Pulmagen Therapeutics is a Private company.

  • What is Pulmagen Therapeutics’s current revenue?

    The current revenue for Pulmagen Therapeutics is .

  • Who are Pulmagen Therapeutics’s investors?

    Amundi Private Equity Funds, Forbion, MVM Partners, Molten Ventures, and TTP Venture Managers are 5 of 6 investors who have invested in Pulmagen Therapeutics.

  • Who are Pulmagen Therapeutics’s competitors?

    Minerva Neurosciences, Thetis Pharmaceuticals, Lung Therapeutics, Moerae Matrix, and Verona Pharma are some of the 30 competitors of Pulmagen Therapeutics.

  • When was Pulmagen Therapeutics acquired?

    Pulmagen Therapeutics was acquired on 14-Aug-2014.

  • Who acquired Pulmagen Therapeutics?

    Pulmagen Therapeutics was acquired by Skyepharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »